Interactive Investor

Sareum Holdings Q&A: drug developer holds AGM

17th December 2021 16:32

Investor Meet Company from ii contributor

The board of Sareum Holdings (LSE:SAR) present their AGM proceedings and answer a range of investor questions. The event, held on 16 December 2021, is brought to you by our friends at Investor Meet Company.

Highlights

Q&A: 21:05

About the Company

Sareum Holdings is engaged in drug discovery and development. The company is focused on cancer and autoimmune diseases and licensing them to pharmaceutical and biotechnology companies. The company's drug programmes include Checkpoint Kinase 1 (CHK1), Aurora+FLT3 Kinase and Tyrosine Kinase 2- autoimmune diseases (TYK2), Aurora+FLT3 kinase and TYK2 kinase-cancer. Its Chk1 programme is the advanced programme and shows potency in disease models of lung and colon cancers in combination with chemotherapy; acute myeloid leukemia (AML) and B-cell lymphoma, and head and neck cancers in combination with radiotherapy. TYK2 kinase programme focuses on developing a series of TYK2 inhibitors that can be dosed orally against various autoimmune and inflammatory disorders.

These articles are provided for information purposes only.  Occasionally, an opinion about whether to buy or sell a specific investment may be provided by third parties.  The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.

Full performance can be found on the company or index summary page on the interactive investor website. Simply click on the company's or index name highlighted in the article.